Vertex Pharmaceuticals, in collaboration with CRISPR Therapeutics, is advancing CTX001, a CRISPR-Cas9 gene-editing therapy targeting β-thalassemia and sickle cell disease (SCD). The long-term follow-up study aims to assess the safety and efficacy of CTX001 in patients previously treated in parent studies. The market for gene therapies in hematologic diseases is expanding, driven by increasing prevalence and demand for innovative treatments. Successful outcomes could position CTX001 as a leading therapy in this niche, potentially capturing significant market share and enhancing Vertex's portfolio, especially as competition intensifies with other gene-editing technologies and therapies in development.